Our pre-clinical data support a unifying hypothesis in which both hIgG1 and hIgG2 anti-CTLA-4 mAbs employed in the clinic act to promote preferential depletion of tumor-infiltrating Treg cells and increase the intra-tumoral Teff/Treg cell ratio associated with tumor rejection. The gene discussed is CTLA4; the disease is neoplasm.